Tag: plasma

LIVERMORE, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Inertia Enterprises, the commercial fusion energy company, today announced the formation of its Science and Technology Advisory Board (STAB). The newly formed advisory board is an independent group of the world's foremost experts in fusion plasma physics, high-energy laser systems, large-scale program execution, target fabrication, and nuclear materials science. Its purpose is to provide rigorous, independent technical assessment across Inertia's physics, target, laser, and power plant development programs as the company prepares to deliver grid-scale fusion energy in the 2030s.

EB612, a first-in-class long-acting PTH(1-34) oral peptide  for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026

– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –

BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.¹ The results showed that TALVEY^® (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72.0%, and clinically meaningful reduction of up to 53.0% in the risk of death, compared to the standard regimen of daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM).¹ Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months.¹  

— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile —